Victrex (VCT) Earns “Buy” Rating from Liberum Capital
A number of other equities research analysts have also recently commented on the stock. Berenberg Bank raised their price target on shares of Victrex from GBX 1,320 ($17.91) to GBX 1,380 ($18.72) and gave the stock a buy rating in a report on Friday, February 23rd. Numis Securities restated a hold rating and issued a GBX 2,550 ($34.59) price target (up from GBX 2,300 ($31.20)) on shares of Victrex in a report on Monday, February 12th. BNP Paribas restated an underperform rating on shares of Victrex in a report on Thursday, April 5th. Credit Suisse Group raised their price target on shares of Victrex from GBX 2,650 ($35.95) to GBX 2,800 ($37.98) and gave the stock an outperform rating in a report on Wednesday, March 28th. Finally, Peel Hunt restated a hold rating and issued a GBX 2,400 ($32.56) price target on shares of Victrex in a report on Monday, February 12th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company. The stock has an average rating of Hold and an average price target of GBX 2,376.80 ($32.24).
VCT opened at GBX 2,764.66 ($37.50) on Monday. Victrex has a twelve month low of GBX 1,826 ($24.77) and a twelve month high of GBX 2,772 ($37.60).
Victrex Company Profile
Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. It operates through two segments, Victrex Polymer Solutions and Invibio Biomaterial Solutions. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, dental, trauma, knee, cardiovascular, and orthopedic applications.
Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.